Navigation Links
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Date:3/2/2013

PARIS and TARRYTOWN, N.Y., March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab.  Other exploratory endpoints included pharmacokinetic, biomarker, and efficacy parameters.  The efficacy data showed that treatment with four weekly subcutaneous injections of dupilumab at either 150 milligrams (mg) or 300mg per week, significantly improved the signs and symptoms of patients with moderate-to-severe atopic dermatitis (AD) whose disease was not adequately controlled with topical medications.  Specifically, patients treated with dupilumab had significant improvements in body surface area (BSA) score, Investigator Global Assessment (IGA) score, and Eczema Area Severity Index (EASI) from baseline to week 4 compared to placebo (p<0.05 vs. placebo for all measures and doses).  The significant improvements in BSA, IGA, and EASI scores were maintained at week 8 in the 300mg dose group (p<0.05 vs. placebo).  A responder analysis demonstrated that at week 4, 54.5% of patients treated with the 150mg dose and 71.4% of patients treated with the 300mg dose achieved a reduction in EASI score of 50% or greater compared to 18.8% with placebo (p<0.05).  The most common adverse events (AEs) were nasophar
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
2. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
3. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
4. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
5. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
8. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
9. Sanofi Pasteur to add 2D barcode to six more vaccines
10. Sanofi US Launches Collaborate Activate Innovation Challenge
11. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Computerized tomographic (CT),colonography, also known as virtual colonoscopy, ... flexible tube with a camera to view the,lining ... detect cancer and,precancerous polyps and could serve as ... the results of the American College of,Radiology Imaging ...
... Department of,Justice announced today that it will not ... (CRC) to develop and publicize model contract language,for ... Department said,the language is not likely to be ... in contract negotiations, potentially reducing costs,and shortening the ...
Cached Medicine Technology:Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 2Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 3Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 4Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Hepatitis ... C Relapsers and Nonresponders, KENILWORTH, N.J., Nov. 15 ... European Commission on,October 30 approved 48-week standard-dose PEGINTRON(TM) (peginterferon,alfa- 2b, ... mg,daily) combination therapy for retreating adult patients with chronic,hepatitis C ...
... largely on children entering school ready to learn, and ... children for school entry. A new study finds that ... for school, suggesting that intervention could help boost readiness ... Laval University, the University of Montreal, and the University ...
... some prescriptions , , WEDNESDAY, Nov. 14 (HealthDay News) -- ... allow certain drugs to be sold by pharmacists without ... to arguments for and against the proposal by representatives ... at the day,s end, the FDA officials said they ...
... Response Genetics, Inc.,(Nasdaq: RGDX ) a company ... cancer, today announced its consolidated financial results for,the ... September 30, 2007. "The third quarter of ... physician and investment communities," said Kathleen Danenberg,President and ...
... Dragon Pharmaceutical Inc.,(TSX: DDD; OTC BB: DRUG; BBSE: ... and nine months ended September 30, 2007, showing ... antibiotic business. Meanwhile,the Company also announced the sale ... a separate press release. Highlights for the ...
... Holdings, Inc. (the,"Company") today announced its operating results for ... Three Months Ended September 30, 2007 Net Revenues ... for the three months,ended September 30, 2007, increased by ... Patient days increased by 289 during the 2007 period.,During ...
Cached Medicine News:Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 3Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 4Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 5Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 6Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 7Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 8Health News:Environment plays key role in children's readiness for school 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Response Genetics Reports Third Quarter 2007 Financial Results 2Health News:Response Genetics Reports Third Quarter 2007 Financial Results 3Health News:Response Genetics Reports Third Quarter 2007 Financial Results 4Health News:Response Genetics Reports Third Quarter 2007 Financial Results 5Health News:Response Genetics Reports Third Quarter 2007 Financial Results 6Health News:Response Genetics Reports Third Quarter 2007 Financial Results 7Health News:Response Genetics Reports Third Quarter 2007 Financial Results 8Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 2Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 3Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 4Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 2Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 3Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 4Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 5Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 6Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 7Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 8Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 9Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 10Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 11Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 12Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 13Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 14Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 15
Pipetman 8X200 Multichannel Pipette is an eight-channel, fully adjustable, air-displacement pipette having a useful volume range from 20 L to 200 L. Robustwith the usual Gilson qualities this pipette...
Inquire...
... is precision, ergonomics, and value! , ... soft non-slip, contoured handle , Finer control ... action , Stress-free tip ejection with long, ... easy decontamination and sterilization without the need ...
... Lightest Pipettor , , The Shortyavailable with ... of how our face-to-face relationship with the scientific ... that make pipetting easier and more effective., ... pipettors., Gets you closer to the working ...
Medicine Products: